{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T09:45:27Z","timestamp":1777715127039,"version":"3.51.4"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Immunocompromised adults hospitalized for coronavirus disease 2019 (COVID-19) remain at high risk for morbidity. Despite remdesivir\u2019s approval for treatment of COVID-19, real-world evidence on its early use, particularly in patients infected with evolving Omicron-era subvariants, remains limited. Contemporary evidence is essential to support hospital pharmacy practice and antiviral stewardship.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study using the Premier Healthcare Database. Adult immunocompromised patients hospitalized for COVID-19 from December 2021 to December 2024 were included. Patients with COVID-19 present-on-admission who received remdesivir within the first 2 hospital days were compared to untreated patients using 1:1 propensity score matching. The outcomes assessed were 14- and 28-day all-cause mortality. Subgroup analyses assessed outcomes stratified by oxygen requirements and specific immunocompromising conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 22,808 matched patients, early remdesivir use was associated with significantly lower 14-day (hazard ratio [HR], 0.75; 95% CI, 0.69-0.82; P &amp;lt; 0.0001) and 28-day mortality (HR, 0.80; 95% CI, 0.74-0.86; P &amp;lt; 0.0001). Mortality reductions were observed across early and later Omicron periods and among patients with or without supplemental oxygen requirements. Subgroup analyses showed similar survival benefit in patients with cancer, including hematologic malignancies, as well as transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Early remdesivir initiation was associated with clinically meaningful and significant survival benefits in immunocompromised patients hospitalized for COVID-19, with these associations persisting in the Omicron subvariant era. These findings highlight the potential benefit of early antiviral treatment in this vulnerable population while underscoring the need for further prospective studies, including randomized controlled trials, to confirm causal effects and refine treatment strategies. Clinical pharmacists have a pivotal role in ensuring institutional protocols remain aligned with current evidence so that eligible high-risk patients consistently receive appropriate therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag036","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T12:46:44Z","timestamp":1770295604000},"page":"S2931-S2939","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of remdesivir in immunocompromised patients hospitalized due to SARS-CoV-2 Infection: Insights to inform pharmacy practice"],"prefix":"10.1093","volume":"83","author":[{"given":"Andre C","family":"Kalil","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center , Omaha, NE ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chidinma","family":"Chima-Melton","sequence":"additional","affiliation":[{"name":"Cardiopulmonary Division, Pipeline Health , Los Angeles, CA"},{"name":"Tele-ICU Inc. , Los Angeles, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Naslazi","sequence":"additional","affiliation":[{"name":"Evidence and Access , Certara ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heribert","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Medical Affairs, Gilead Sciences , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpesh N","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of California Irvine , Irvine, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha N","family":"Pettit","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UChicago Medicine , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Baylor University Medical Center , Baylor Scott & White Health, Dallas, TX"},{"name":"Burnett School of Medicine at TCU , Fort Worth, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"issue":"10","key":"2026041222234155700_zxag036-B1","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults","volume":"331","author":"Martinson","year":"2024","journal-title":"JAMA"},{"issue":"27","key":"2026041222234155700_zxag036-B2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.15585\/mmwr.mm7127a3","article-title":"Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19\u2014COVID-NET, 10 states, March 2020\u2013February 2022","volume":"71","author":"Singson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026041222234155700_zxag036-B3","author":"Taylor"},{"key":"2026041222234155700_zxag036-B4","author":"Taylor CA; RESP-NET Hospitalization Surveillance Team"},{"issue":"4","key":"2026041222234155700_zxag036-B5","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40121-025-01122-5","article-title":"The impact of the COVID-19 omicron variant on immunocompromised patients: ICU admissions and increased mortality","volume":"14","author":"Pander","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"4","key":"2026041222234155700_zxag036-B6","doi-asserted-by":"publisher","first-page":"e1259","DOI":"10.1002\/iid3.1259","article-title":"Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review","volume":"12","author":"Bytyci","year":"2024","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"2026041222234155700_zxag036-B7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/13696998.2021.2002063","article-title":"Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2","volume":"24","author":"Di Fusco","year":"2021","journal-title":"J Med Econ"},{"issue":"3","key":"2026041222234155700_zxag036-B8","doi-asserted-by":"publisher","first-page":"100628","DOI":"10.1016\/j.trre.2021.100628","article-title":"The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis","volume":"35","author":"Ao","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"key":"2026041222234155700_zxag036-B9","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.eclinm.2023.101965","article-title":"Vaccines and therapeutics for immunocompromised patients with COVID-19","volume":"59","author":"Shoham S, Batista C, Ben Amor Y, et al","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"5","key":"2026041222234155700_zxag036-B10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3348\/kjr.2023.0992","article-title":"Clinical and imaging characteristics of SARS-CoV-2 breakthrough infection in hospitalized immunocompromised patients","volume":"25","author":"Lee","year":"2024","journal-title":"Korean J Radiol"},{"key":"2026041222234155700_zxag036-B11","author":"COVID-19 Treatment Guidelines Panel"},{"key":"2026041222234155700_zxag036-B12","doi-asserted-by":"publisher","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"suppl 4","key":"2026041222234155700_zxag036-B13","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1093\/cid\/ciae510","article-title":"Remdesivir-associated survival outcomes among immunocompromised patients hospitalized for COVID-19: real-world evidence from the omicron-dominant era","volume":"79","author":"Mozaffari","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026041222234155700_zxag036-B14","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1186\/s12879-024-09708-z","article-title":"Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1\/BQ.1.1\/XBB.1.5","volume":"24","author":"Molina","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"6","key":"2026041222234155700_zxag036-B15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae202","article-title":"Remdesivir is associated with reduced mortality in patients hospitalized for COVID-19 not requiring supplemental oxygen","volume":"11","author":"Mozaffari","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2026041222234155700_zxag036-B16","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2026041222234155700_zxag036-B17","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac502","article-title":"Early outpatient treatment with remdesivir in patients at high risk for severe COVID-19: a prospective cohort study","volume":"9","author":"Rajme-L\u00f3pez","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"2026041222234155700_zxag036-B18","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/v17020168","article-title":"Remdesivir and obeldesivir retain potent antiviral activity against SARS-CoV-2 omicron variants","volume":"17","author":"Rodriguez","year":"2025","journal-title":"Viruses"},{"issue":"1","key":"2026041222234155700_zxag036-B19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N Engl J Med"},{"key":"2026041222234155700_zxag036-B20","author":"Gilead Sciences"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag036\/66834545\/zxag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_3\/S2931\/66834545\/zxag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/Supplement_3\/S2931\/66834545\/zxag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T02:23:50Z","timestamp":1776047030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/Supplement_3\/S2931\/8470591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":20,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2026,2,9]]},"published-print":{"date-parts":[[2026,4,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag036","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,1]]},"published":{"date-parts":[[2026,2,9]]}}}